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1. Introduction
While surgery, radiation therapy, treatment with luteinizing 
hormone-releasing hormone (LHRH) antagonists and other 
drugs are available for patients with prostate carcinoma up 
to the stage that the tumour is hormone dependent, no fully 
effective therapy is available for the treatment of androgen-
independent hormone-refractory prostate carcinoma 
(HRPC). With the idea of developing a therapeutic antibody 
directed at such cancers, we made a monoclonal antibody 
(Moab) that causes lysis of DU145 androgen-independent 
carcinoma prostate cells in the presence of complement 
(Talwar et al. 2001). This antibody could, however, kill only 
about 80% of these cells, as the epitope recognized by this 
antibody was present only on about 80% of cells and not on 
all. Given that micro-heterogeneity exists in such cancers, an 
attempt was made to raise a complementary Moab. 
We report a new monoclonal 2C4 which, in combination 
with the previously developed antibody, causes 100% killing 
of not only DU145 but also PC3 androgen-independent 
prostate carcinoma cells. This antibody does not bind to the 
peripheral blood cells of healthy donors of blood.
2. Materials and methods
2.1 Cell lines
Androgen-independent human prostate cells DU145 were 
obtained from the American-type cell culture (ATCC No. 
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HTB-81). These cells were originally derived from a human 
prostate adenocarcinoma that metastasized to the brain by 
Stone et al. (1978). The cells are epithelial, grow in isolated 
islands on plastic Petri dishes, and form colonies in soft agar 
suspension culture. Another cell line of androgen-indepen-
dent prostate cancer PC3 was also obtained from ATCC 
(ATCC No. CRL-1435). DU145, PC3 and myeloma fusion 
partner SP2/o were cultured in Dulbecco minimum essential 
medium (DMEM) supplemented with 10% foetal calf serum 
(FCS) and antibiotic–antimycotic mixture (penicillin 100 U/
ml, streptomycin 100 μg/ml and amphotericin-B 250 ng/ml) 
(Gibco-BRL Life Technologies). The cells were subcultured 
before they reached 70% confl uency. Myeloma cells SP2/o 
were treated with BM-Cycline (Roche Applied Sciences) for 
three weeks to ensure that these were free of Mycoplasma. 
Cells were harvested by treatment with trypsin–EDTA 
(0.05% trypsin, 0.02% EDTA), followed by centrifugation 
at 1250 rpm at room temperature for 5 min. 
2.2 Complement
Prescreened class 1 rabbit complement obtained from Cedar 
Lane Laboratories, USA was reconstituted in MQ water 
followed by fi ltration through a fi lter with a 0.22 μm pore 
size. The concentration of complement for optimal lysis in 
the presence of excess of antibody was determined. 
2.3 Immunization of animals
Cells, after washing with 10 mM phosphate buffered 
saline (PBS), pH 7.2, were resuspended at 106 cells/ml. 
BALB/c inbred mice were immunized intraperitoneally 
(i.p.) with DU145 cells (1 × 106 cells/ mouse) emulsifi ed 
with complete Freund adjuvant (CFA). After 2 and 4 weeks, 
boosters comprising the same number of cells were given 
i.p. with incomplete Freund adjuvant (IFA). Animals that 
developed high antibody titres against the cells were 
injected intravenously with 106 cells in PBS 3 days prior to 
harvesting spleen cells for fusion.
2.4 Hybridoma generation
The splenocytes separated on Ficoll–Hypaque density 
gradient (Amersham-Pharmacia Biotech) were washed with 
PBS and fused with the SP2/o mouse myeloma cells at a 1:
1 ratio in 50% (w/v) solution of polyethylene glycol 1500 
(Sigma, St Louis) as per Kohler and Milstein (1975). The 
hybridized cells were selected in 96-well tissue culture plates 
in HAT medium (DMEM supplemented with 20% FCS, 1% 
antibiotic–antimycotic mixture, 100 mM hypoxanthine, 0.4 
mM aminopterin and 16 mM thymidine; Sigma, St Louis). 
Hybrid cells were screened for immunoreactivity with 
DU145 cells by solid-phase enzyme-linked immunosorbent 
assay (ELISA) as described below. These cells were cloned 
by limiting dilutions and sub-cloned three to four times to 
obtain stable cell lines secreting Moabs.
2.5 FACS
DU145 cells were harvested by treatment with trypsin–
EDTA, centrifuged at 1250 rpm at room temperature for 5 
min. The cell pellet was washed once with 10 mM PBS.
1 × 105 cells/tube was taken in 100 μl of FACS buffer (1% 
BSA, 0.2% sodium azide dissolved in 10 mM PBS). Culture 
supernatant of the hybrids was added and the tubes were 
incubated for 1 h at 4°C. Cells were washed with FACS 
buffer and stained with fl uorescein isothiocynate (FITC)-
conjugated goat anti-human immunoglobulin (Ig)G Fcγ 
(Jackson ImmunoResearch Laboratories) for 1 h at 4°C. 
Cells were washed and suspended in 0.5% paraformaldhyde 
solution in PBS and fl uorescence assorted cell sorter (FACS) 
carried out in a Becton Dickinson LSR Model (Becton 
Dickinson, San Jose, CA). The data were analysed using the 
WinMdi software (version 2.9).
2.6 Antibody isotyping
Antibody 2C4 was classifi ed for its isotype using the mouse 
Ig isotyping ELISA kit (BD PharmingenTM, BD Biosciences, 
USA). 
2.7 Antibody purifi cation and quantifi cation
Purifi cation of the Moab was carried out by affi nity column 
chromatography. The culture supernatant was loaded on 
a Protein-A affi nity column as per the manufacturer’s 
instructions (Pharmacia Inc. Stockholm, Sweden). Elution 
was carried out with 0.1 M glycine buffer pH 2 and 
immediately neutralized to pH 7 using 1 M Tris pH 12. The 
eluate was dialysed against 10 mM PBS and concentrated 
in an Amicon ultrafi ltration chamber using a 60 kDa cut-off 
membrane. The protein concentration was determined by the 
Micro BCA Kit, (Pierce [Thermo], USA). 
2.8 Western blot
Lysates of DU145 and PC3 cells were prepared in buffer 
containing the detergent NP-40 and a protease inhibitor 
cocktail (Calbiochem, USA). SDS-PAGE was carried out 
by standard procedures and antibody-reactive moieties were 
visualized by enhanced chemiluminescence (Biological 
Industries, Israel), subsequent to western blotting on 
HybondTM membranes (Millipore, USA).
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2.9 Immunofl uorescence
DU145 and PC3 prostate cancer cells (104/well) were seeded 
in a cell culture plate. Adherent cells were washed thrice with 
PBS and incubated with 10 μg/100 μl of purifi ed antibodies 
for 1 h at 4°C. After washing with PBS, the cells were stained 
with FITC-conjugated goat anti-human IgG Fcγ (Jackson 
Immuno Research Laboratories, USA) for 1 h at 4°C. The 
cells were washed with FACS buffer and suspended in 
0.5% paraformaldehyde. Images were recorded in bright 
fi eld as well as by using a blue fi lter under a fl uorescence 
microscope (Nikon, Eclipse TE2000-U, Japan). 
2.10 Cytotoxicity assay
The intrinsic property of the antibody to lyse the cells in the 
presence of complement was measured by the colorimetric, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. Cell suspensions of 4 × 104 DU145 or 
PC3 cells/100 μl were taken in DMEM supplemented with 
10% FCS in 96-well microtitration plates. The plates were 
incubated overnight at 37°C in a humidifi ed atmosphere of 
5% CO
2
 for the cells to adhere to the plate. The supernatant 
was removed and the purifi ed antibodies, alone or in 
combination, dissolved in culture medium at a concentration 
ranging from 2.5 to 10 μg/100 μl/well, were added. The 
plates were incubated for 1 h at 37°C. Thereafter, 100 μl 
of medium containing 12% rabbit complement was added. 
Cells in fresh medium without antibody or complement were 
kept as control. Each assay was carried out in triplicate. The 
supernatant was removed and 25 μl of MTT reagent in PBS 
was added. The plates were further incubated for 2–4 h 
till crystals formed. To dissolve the crystals, 75 μl of lysis 
buffer was added per well. Per cent cytotoxicity (X’) was 
calculated by the formula:
      X’ = (1 – X / R1) × 100
Where X = optical density of the test wells; R1 = optical 
density of the control wells containing culture medium.
2.11 In vivo testing of antibodies against DU145 tumour 
cells
Studies were carried out in athymic nude mice. Tumour was 
induced by injecting 3 × 106 DU145 cells subcutaneously 
in the lower fl anks of mice. Twenty microgram each of 
fi lter-sterilized Moab 2C4 and Moab 730 dispensed in 100 
μl of 10 mM PBS, pH 7.2 were injected thrice weekly at 
the tumour site; controls received an equal volume of PBS. 
Tumour growth was measured by Vernier calipers at 10-day 
intervals. As tumour is a spherical mass, the volume was 
calculated using the formula 4/3πr3 where r = mean length 
measured by Vernier calipers in millimeters/2.
3. Results
3.1 Generation of monoclonal antibody and isotyping
Four fusions of splenocytes derived from DU145-immunized 
mice with SP2/o mouse myeloma cells were carried out. Six 
hybrid cell clones were found to be positive for antibodies 
reacting with DU145, as observed by fl owcytometry. The 
monoclonal stage was attained after sub-cloning thrice 
by dilution each time to single-cell level. Moab 2C4 was 
selected for the cytotoxicity assay, alone and in combination 
with Moab 730.
3.2 Reactivity of Moab 2C4
Moab 2C4 bound to live DU145 as well as PC3 cells, as seen 
by fl owcytometry (fi gure 1a and 1b). However, it did not 
bind at all with freshly isolated PBLs isolated from normal 
healthy donors (fi gure 1c). 
3.3 Effect of Moab 2C4 on DU145 and PC3
Moab 2C4 was found to be cytotoxic to both PC3 and 
DU145 cells in the presence of complement as seen by the 
MTT assay (fi gure 2). Complement, at a concentration of up 
to 12%, exercised minimal toxicity on the cells. However, 
in the presence of the antibody, cytotoxicity was clearly 
noticeable, which increased with increasing concentrations 
of the antibody. At antibody-saturating levels, the percentage 
of DU145 cells lysed was 83 ± 8.7% (fi gure 2a) and of 
PC3 cells it was 80 ± 5.1% (fi gure 2b). The complement-
mediated cytotoxicity exercised by Moab 730 on these cells 
at antibody-saturating concentrations was of a similar order 
(Talwar et al. 2001). When a combination of Moabs 730 and 
2C4 was employed, it caused 100% lysis of both PC3 and 
DU145 cells (fi gure 2). 
The fact that all tumour cells were killed by the 
combination of the two Moabs and that only partial killing 
of the cells occurred after incubation with either one of 
the Moabs in the presence of complement, was further 
confi rmed by the following experiment. Viable cells of 
DU145 (fi gure 3a) and PC3 (fi gure 3b) were quantifi ed by 
MTT assay after incubation with Moab 2C4 or Moab 730 in 
the presence of complement for 12 h. Fresh culture medium 
supplemented with 10% FCS was added in replicate wells at 
12 h and incubation continued for another 24 h. At the end of 
this period, the viable cells were quantifi ed by MTT assay.
Data from fi gure 3 show that viable cells were observed 
in both the tumour cell lines (27–28% in DU145 and 26–
29% in PC3 cells) after 12 h of culture with a single Moab 
in the presence of complement. These numbers increased 
after culture for a further 24 h with fresh medium and 10% 
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Figure 1. For caption, see page No. 913. Figure 2. For caption, see page No. 913.
FCS. On the other hand, when DU145 and PC3 cells were 
incubated with a combination of Moab 2C4 and Moab 730 in 
the presence of complement, no viable cells were measurable 
at either 12 h or after an additional 24 h of incubation in the 
culture medium (fi gure 3).
Killing of androgen-independent prostate carcinoma 
cells by a combination of Moab 2C4 and Moab 730 was also 
evident by phase-contrast photomicrographs (fi gure 4). 
It was appropriate to determine whether the two Moabs 
bound to the same or different surface epitopes on the cells. 
Immunofl uorescence studies with Moab 730 revealed that it 
was bound to epitopes dispersed all along the membranes of 
DU145 and PC3 cells (fi gure 5). On the other hand, binding 
of Moab 2C4 was confi ned and patchy. Another indication 
that the two Moabs bound to different epitopes is furnished 
by the western blot carried out on cell lysate of DU145 and 
PC3 cells (fi gure 6). 
3.4 In vivo studies in nude mice
DU145 cells have the ability to form tumours in athymic 
nude mice. Investigations were carried out to determine 
whether the combination of the two antibodies prevented the 
establishment of tumours in nude mice. Figure 7 gives the 
results. Whereas administration of PBS had no perceptible 
infl uence on growth of the tumour, administration of 10 
μg each of Moabs 2C4 and 730 thrice weekly prevented 
formation of the tumour in nude mice. Owing to limitations 
in the availability of nude mice and lack of maintenance space 
for these mice, in vivo studies could be carried out only on 
DU145 tumours, even though the in vitro cytotoxicity of these 
antibodies was established in both DU145 and PC3 cells.
4. Discussion
Prostate cancer is among the largest killer of men due to 
cancer in some countries. According to the Surveillance 
Epidemiology and End Results fact report of the National 
Cancer Institute, USA, it is estimated that 192 280 men will 
be diagnosed with and 27 360 men will die of cancer of the 
prostate in 2009 in the USA alone (http://seer.cancer.gov/csr/
1975_2006/results_single/ sect_01_table.01.pdf). Data from 
other countries are not available, though prostate carcinoma 
occurs in all countries. Fatalities invariably occur at a stage 
when the tumour has metastasized, is androgen-independent 
and refractory to hormones. Currently available drugs are of 
partial benefi t over a limited time span.
 The objective of the present study was to develop 
Moabs that can act selectively on such tumours and bring 
about their demise. Studies were carried out on cells of two 
standard androgen-independent prostate carcinoma cell lines 
obtained from ATCC. A monoclonal antibody developed 
previously in our laboratory, Moab 730, caused lysis of 
both DU145 and PC3 cells in the presence of complement. 
The limitation of this Moab, however, was that it killed 
only 80% of such cells and the residual viable cells took 
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Figure 3. Evidence for partial killing and survival of a fraction 
of DU145 (a) and PC3 cells (b) after incubation with either Moab 
2C4 or Moab 730 in the presence of complement. After 12 h of 
incubation with antibodies and complement, the viable cells were 
quantifi ed by MTT assay. In replicate wells, fresh medium was 
added at 12 h and culture was continued for another 24 h. No viable 
cells were observed in the set in which a combination of Moab 2C4 
and Moab 730 were employed either at 12 h or at 36 h of culture 
with fresh culture medium supplemented with 10% FCS.
Figure 1. Binding of monoclonal antibody 2C4 on DU145, 
PC3 and peripheral mononuclear cells (PBMCs). Moab 2C4 was 
incubated with viable DU145 (a), PC3 prostate cancer cells (b) 
and peripheral blood leukocytes (PBLs) (c) from normal healthy 
donors. Binding was revealed by using fl uorescein isothiocyanate 
(FITC)-labelled goat anti-mouse antibody by a fl uorescence 
activated cell sorter (FACS). 
Figure 2. Cytotoxicity of Moab 2C4 individually and in 
combination with Moab 730 on PC3 and DU145 in the presence 
of complement as determined by MTT assay. (a) DU145, (b) PC3 
cells and (c) peripheral blood leukocytes (PBLs) from normal 
healthy donors. Symbols represent values in different experiments 
and bars are the mean values.
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over in course of time. The aim of the present work was 
to develop a complementary antibody that could kill cells 
resistant to Moab 730. The data presented show that the new 
Moab 2C4, in combination with Moab 730, can kill 100% 
of both DU145 and PC3 cells. Killing was gauged not only 
morphologically but also by MTT assay, which quantitates 
viable cells by forming formazan crystals. 
 The binding pattern of the two antibodies differs, as also 
their isotypes. Moab 730 is IgG1κ and Moab 2C4 is IgG2aκ. 
The killing of both types of tumours was evident in vitro and 
was confi rmed in vivo for DU145 cells. The development 
of tumour in nude mice was effectively prevented by a 
combination of the two antibodies. The stage is now set 
to convert the two antibodies into chimeric/humanized 
recombinant antibodies for therapeutic use.
Several murine/chimeric/humanized antibodies alone, or 
attached to payloads, have been approved by the US Food 
and Drug Administration (FDA) and other drug regulatory 
authorities for the treatment of cancers and other chronic 
disorders. In the past 12 years, 9 Moabs were approved
for clinical use by the US FDA for cancer therapy and
about 30 Moabs – murine, chimeric or humanized – are 
currently undergoing human phase II/III clinical testing 
as cancer therapy. Out of the 9 FDA-approved Moabs
for the treatment of cancers, 6 Moabs act by a mech-
anism of cytolytic action in the presence of complement, i.e. 
complement-dependent cytotoxicity (CDC), or by antibody-
dependent cell cytotoxicity (ADCC) (Liu et al. 2008). The 
fi rst Moab of this type approved by the US FDA for human 
use was a murine anti-CD3 monoclonal OKT3, employed 
for the treatment of organ transplant rejection (Kunq et 
al. 1979). The fi rst Moab approved for the treatment of 
cancer was rituximab (RituxanTM), a chimeric anti-human 
anti-CD20, approved in 1997 for the treatment of non-
Hodgkin lymphoma. The use of antibodies such as rituximab 
(RituxanTM) (Glennie et al. 2007), Campath-1HTM (Bindon et 
al. 1988), ibritumomab (ZevalinTM) (Chinn et al. 1999) and 
others which act by a CDC mechanism provide support for 
the safety and clinical effi cacy of such antibodies. 
Although some mouse-derived Moabs such as ibritumomab 
(ZevalinTM) and tositumomab (BexxarTM) are approved by 
drug regulatory authorities for life-threatening conditions, 
technologies are available to convert mouse-derived 
antibodies into chimeric or humanized antibodies. We have 
earlier converted a mouse Moab against human chorionic 
gonadotrophin (hCG) into a recombinant chimeric antibody 
which can be expressed in plants at high yield (Kathuria et 
al. 2002a, b). This antibody with mouse variable regions 
fused to human IgG
1
κ binds with T-lymphoblastic leukaemia 
and histiocytic lymphoma cells (Kabeer et al. 2005). The 
Figure 4. Microphotographs of the prostate carcinoma cells before and after incubation with monoclonal antibodies, in the presence of 
complement. (a) DU145 cells without antibody. (b) DU145 cells lysed after co-incubation with Moabs 2C4 and 730 in the presence of 
12% complement. (c) PC3 cells without antibody and complement, and (d) PC3 cells after co-incubation with Moabs 2C4 and 730 in the 
presence of 12% complement. 
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Figure 5. Binding pattern of Moabs 2C4 and 730 on DU145 and PC3 cells. (a) Immunofl uorescence on PC3 cells with 2C4 under low 
bright fi eld at 10x magnifi cation. (b) 2C4 antibody-binding cell seen at 40x magnifi cation. (c) Immunofl uorescence due to binding of Moab 
730 to DU145 40x, and (d) to PC3 cells, 40x as revealed by using fl uorescein isothiocyanate (FITC)-labelled goat anti-mouse antibody.
Figure 6. Western blot of Moab 730 and 2C4 on lysate of DU145 
and PC3 cells. Lanes 1–3 with lysate of DU145 and lanes 4–6 with 
lysate of PC3. Lane M, Marker; lanes 3 and 6, control; lanes 2 and 
5, Moab 2C4; lanes 1 and 4, Moab 730.
Figure 7. Inhibition of establishment of DU145 prostate tumour 
in nude mice by a combination of Moabs 2C4 and 730. 3 x 106 
DU145 cells were implanted subcutaneously in the lower fl anks 
of mice. 20 μg each of fi lter-sterilized Moab 2C4 and Moab 
730 dispensed in 100 μl of 10 mM PBS pH 7.2 was injected
thrice weekly at the tumour site with controls receiving an equal 
volume of PBS only. The fi gure gives the mean tumour size at 
different time points in six animals in each group with standard 
deviation.  
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antibody was used to deliver diferuloylmethane (curcumin) 
selectively to tumour cells. This immunotoxin was effective 
in killing 100% of the MOLT-4 T-lymphoblastic leukaemia 
and U-937 histiocytic lymphoma cells that expressed hCG 
ectopically (Vyas et al. 2009). 
Besides Moab 730 (Talwar et al. 2001), the only other 
Moab reported in the literature against prostate carcinoma 
cells is HuJ591, which is directed against prostate-specifi c 
membrane antigen (Bander 2003). Three phase I studies 
have been carried out with this humanized Moab linked 
to the β-emitting radiometals yttrium 90 and lutetium 177, 
and the third using a cytotoxin (DM1). The radiolabelled 
antibody was found useful for imaging of tumours and for 
delivery of radiation selectively to the tumour cells (Bander 
et al. 2003).
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